Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.”In the company’s words, NCT04935177 on ClinicalTrials.gov
- Main trialPhase 3
- “An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care”In the company’s words, NCT04935177 on ClinicalTrials.gov
- Other names
- Intravenous immunoglobulin
Other drugs for Kidney Transplantation in Highly Sensitized Patients
- Migalastat HClAmicus Therapeutics · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- TegoprubartEledon Pharmaceuticals · Phase 3
- SymvessHumacyte, Inc. · Phase 3
- RoxadustatAstellas · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 20 Jun 2025 | Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026